Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence
Open Access
- 2 May 2018
- journal article
- editorial
- Published by Elsevier in Molecular Therapy
- Vol. 26 (5), 1172-1176
- https://doi.org/10.1016/j.ymthe.2018.04.007
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovationAdvanced Drug Delivery Reviews, 2018
- Registries supporting new drug applicationsPharmacoepidemiology and Drug Safety, 2017
- Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision makingPharmacoepidemiology and Drug Safety, 2017
- Innovative regenerative medicines in the EU: a better future in evidence?BMC Medicine, 2017
- The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisalHealth Technology Assessment, 2017
- Overcoming Challenges Facing Advanced Therapies in the EU MarketCell Stem Cell, 2016
- Deciphering the EU clinical trials regulationNature Biotechnology, 2016
- Methodological Guidelines and Recommendations for Efficient and Rationale Governance of Patient RegistriesEuropean Journal of Public Health, 2015
- The business case for cell and gene therapiesNature Biotechnology, 2014
- Challenges of rare disease research: limited patients and competing prioritiesHaemophilia, 2011